Upcoming WORLD symposium meeting

(with Jason Chew) Lysosomal Disease Network WORLD Symposium meeting The Lysosomal Disease Network (LDN) WORLD Symposium provides an interdisciplinary forum to explore and discuss specific areas of research and clinical.

Wednesday at the JP Morgan Healthcare Conference

With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Wednesday session. I tried to keep them as concise as possible. We will say.

FOLD – Amicus approaches inflection point

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

FOLD – Getting Ready For The New Uptrend

Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report.

FOLD – Bullish on Amicus Therapeutics

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

FOLD – Phase II Amigal Co-administration Update

Amicus Therapeutics released updated data Thursday for its chaperone molecule Amigal (migalastat) for Fabry disease at the American Society of Human Genetics (ASHG) Annual Meeting. Results looked good, continuing to.

FOLD – Quick Take – Amigal P3 Monotherapy

Amicus Therapeutics is expected to unveil results from its Phase III registration trial for migalastat (Amigal) as monotherapy for the treatment of Fabry disease in the third quarter of this.

A flurry of upcoming data before the end of June

With the close of the first half of 2012 upon us, we wanted to highlight some of those expected to report data or regulatory decisions before the end of June..

FOLD – Update on Amicus Therapeutics

Investors in Amicus Therapeutics (NASDAQ: FOLD) are anxiously awaiting data from several ongoing trials in rare-diseases. We initiated coverage on Amicus back in January[link]. We are waiting data from the.

FOLD – Initiating Coverage

FOLD: Initiating Coverage Overview: Now here is an interesting story. Amicus Therapeutics was founded in 2002 by serial entrepreneur and CEO John Crowley. He had previously founded Novozyme seeking a.

Browsing 11 / articles